- 专利标题： Heterocyclic amide for inhibiting RIP1 kinase and uses thereof
-
申请号： US17289642申请日： 2019-10-08
-
公开(公告)号： US11498927B2公开(公告)日： 2022-11-15
- 发明人: Bing Zhou , Wei Tang , Xiangbo Yang , Huimin Lu , Mengying Gao , Yaxi Yang , Huijin Feng
- 申请人： SHANGHAI INSTITUTE OF MATERIA MEDICA, CHINESE ACADEMY OF SCIENCES
- 申请人地址： CN Shanghai
- 专利权人： SHANGHAI INSTITUTE OF MATERIA MEDICA, CHINESE ACADEMY OF SCIENCES
- 当前专利权人： SHANGHAI INSTITUTE OF MATERIA MEDICA, CHINESE ACADEMY OF SCIENCES
- 当前专利权人地址： CN Shanghai
- 代理机构： Rimon Law
- 代理商 Ping Wang
- 优先权： CN201811301267.9 20181102,CN201910712428.1 20190802
- 国际申请： PCT/CN2019/109899 WO 20191008
- 国际公布： WO2020/088194 WO 20200507
- 主分类号： C07D513/04
- IPC分类号： C07D513/04 ; A61P37/06 ; C07D401/12 ; C07D401/14 ; C07D413/12 ; C07D413/14 ; C07D417/12 ; C07D417/14 ; C07D487/04
摘要：
The present invention relates to a heterocyclic amide inhibiting RIP1 kinase and the use thereof, and specifically, to a compound of formula I, its pharmaceutically acceptable salts, stereoisomers, enantiomers, diastereomers, atropisomers, optical isomers, racemates, polymorphs, solvates or isotopically labeled compounds, a pharmaceutical composition comprising the compound, and the pharmaceutical use thereof. The compound is particularly effective for treatment of diseases or disorders mediated by RIP1 kinase.
公开/授权文献
信息查询
